Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Crizotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 11/20 | 1.00 |
| ▸ | ALK known ✓ | Q9UM73 | 7/20 | 1.00 |
| ▸ | ROS1 known ✓ | P08922 | 2/20 | 1.00 |
| ▸ | MST1R known ✓ | Q04912 | 2/20 | 1.00 |
| ▸ | NPM1 known ✓ | P06748 | 1/20 | 1.00 |
| ▸ | EML4 known ✓ | Q9HC35 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 7/20 | 1.00 |
| ▸ | MAP4K3 | Q8IVH8 | 7/20 | 1.00 |
| ▸ | JAK3 | P52333 | 4/20 | 1.00 |
| ▸ | JAK1 | P23458 | 3/20 | 1.00 |
| ▸ | TYK2 | P29597 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 2/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 2/20 | 1.00 |
| ▸ | INSR | P06213 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crizotinib SCHEMBL93829 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL14811801 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL94020 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29831970 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL28844303 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL28844302 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29351506 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL30129754 | 1.00 | MET (1.00) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL29831273 | 0.99 | MET (0.98) | METALKJAK2MAP4K3JAK3 | |
| Crizotinib SCHEMBL1827232 | 0.95 | MET (0.91) | METALKJAK2MAP4K3JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4602150-A1 | A SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | Eyestem Research Private Limited (IN) | 2025-08-20 | — | — | EP | claimed |
| CN-120019141-A | Scalable method for generating Retinal Pigment Epithelial (RPE) cells | 艾视泰研究私人有限公司 | 2025-05-16 | — | — | CN | claimed |
| WO-2024079755-A1 | A SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2024-04-18 | — | — | WO | claimed |
| WO-2024052931-A1 | A PROTOCOL FOR GENERATING NEURAL PROGENITOR CELLS AND IMPLEMENTATIONS THEREOF | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2024-03-14 | — | — | WO | claimed |
| CN-115611861-A | Preparation method of crizotinib | 江苏万邦生化医药集团有限责任公司 | 2023-01-17 | — | — | CN | claimed |
| EP-4731793-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PANCREATIC CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025238172-A1 | COMBINATIONS OF BRAF AND ALK/TRK INHIBITORS FOR COLORECTAL CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | disclosed |
| US-20250269018-A1 | COMBINED CANCER THERAPY WITH AN EPITHELIAL CELL ADHESION MOLECULE (EPCAM) INHIBITOR AND A HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR) INHIBITOR | ACADEMIA SINICA (TW) | 2025-08-28 | — | — | US | disclosed |
| EP-4602150-A1 | A SCALABLE METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIUM (RPE) CELLS | Eyestem Research Private Limited (IN) | 2025-08-20 | — | — | EP | disclosed |
| EP-4562008-A1 | SUBSTITUTED PYRAZOLYL-PYRIDINYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | CELGENE CORPORATION (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-120019141-A | Scalable method for generating Retinal Pigment Epithelial (RPE) cells | 艾视泰研究私人有限公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2023277135-A1 | METHOD FOR PRODUCING CELLS CONSTITUTING NASAL EPITHELIUM, AND CELL POPULATION INCLUDING CELLS CONSTITUTING NASAL EPITHELIUM OR PROGENITOR CELLS THEREOF | 住友化学株式会社 | 2023-01-05 | — | — | WO | disclosed |
| EP-4051288-A1 | ALK INHIBITORS FOR TREATMENT OF ALK-NEGATIVE CANCER AND PLASMA CELL-MEDIATED DISEASES | Universitetet I Oslo (NO) | 2022-09-07 | — | — | EP | disclosed |
| CN-114958764-A | CD20 therapy, CD22 therapy, and combination therapy with CD19 Chimeric Antigen Receptor (CAR) -expressing cells | 诺华股份有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-111007158-B | Method for separating and measuring related substances in preparation process of crizotinib | 上海柏狮生物科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-114901289-A | ALK inhibitors for the treatment of ALK negative cancers and plasma cell mediated diseases | 奥斯陆大学 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022157629-A1 | PHARMACEUTICAL COMBINATIONS OF SOS1 INHIBITORS FOR TREATING AND/OR PREVENTING CANCER | LUPIN LIMITED (IN) | 2022-07-28 | — | — | WO | disclosed |
| CN-114621969-A | Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy | 诺华股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| EP-3280729-B1 | CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) - EXPRESSING CELL | NOVARTIS AG (CH) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250269018-A1 | COMBINED CANCER THERAPY WITH AN EPITHELIAL CELL ADHESION MOLECULE (EPCAM) INHIBITOR AND A HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR) INHIBITOR | EPCAM, MET, HGF | MET 2/4885ALK 618/4885ROS1 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.